VNRX Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 0.3%, SMA50 -9.6%, SMA200 -51.32%). The stock’s 14-day RSI is 48.19 (neutral), while the ATR of 0.03 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -74.84% below its high and over 39.12% above its low. Average 10-day trading volume of 66.70 million shares is significantly above the 3-month average of 10.86 million, indicating heightened recent market interest.

VolitionRx Limited last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.37. This means the shares are trading below this model’s fair value.

VolitionRx Limited (AMEX:VNRX) closed at $0.19 USD, losing -$0.01 (-4.87%) from the previous close of $0.20. The stock is currently mid-range between its 52-week high and low $0.17 and $0.94. With a market capitalization of about $19.07 million, VolitionRx Limited is classified as a micro-cap and shows higher-than-market volatility (beta ~1.36). Key stats such as the average daily volume over the past year has been around 8.43 million shares, trading with heavier-than-usual volume. Headquartered in Henderson, TX, VolitionRx Limited operates in the Healthcare sector and the Medical - Diagnostics & Research industry. Led by CEO Cameron Reynolds, the company employs approximately 85 people and listed since March 02, 2012. VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide.

VolitionRx Limited has 107.59 million shares outstanding. The public float is 77.25 million shares, elevated short interest at 0.38% of float. This equals 298.50 thousand shares. The short ratio is 1.79 days. Institutional investors hold 25.27% of the float. Insiders own 15.83%. Reynolds Cameron John holds 2.55 million shares, Faulkes Martin Charles has 1.67 million shares and Micallef Jacob Vincent has 426.03 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

VolitionRx Limited generated EPS of -$0.23 over the past year. Five-year average earnings growth is 5.38%. The latest quarter delivered EPS of -$0.04. The next quarter is forecast at -$0.04. Next year's EPS is expected at $20.27. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 18 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $5.00 to $1.50. The high target offers 2531.58% upside. The low target suggests 689.47% downside. The mean target is $4.06. This offers 2036.84% upside. VolitionRx Limited earnings surprise history is a consistent trend of beating forecasts. The quarter that ended November 13, 2025, missed forecasts by 0.0%. The prior quarter beat by 20.0%. Over the last six quarters, Apple has recorded several small beats. These include -11.11% in August 14, 2024.

VolitionRx Limited trades at a P/E ratio of -0.9, slightly below the S&P 500 average, with a price-to-sales ratio of 12.86 and a price-to-book ratio of -0.59 indicating negative book value, which may reflect financial stress. The P/FCF stands at -0.96, also below market averages.

Our AI price prediction model suggests that VolitionRx Limited stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -5.91%, with price expected at $0.18 by April 08, 2026, within a range of $0.17 to $0.20 3-Month Outlook: Projected rise of 9.78%, reaching $0.21 by June 22, 2026, with a range of $0.19 to $0.23. 1-Year Outlook: Projected gain of 20.23%, with price at $0.23 by March 25, 2027, within a range of $0.00 to $0.00.

VolitionRx Limited (AMEX:VNRX) shares are up 24.37% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows VolitionRx Limited trading at a premium to the broader market with a P/E of -0.9. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $5.01, suggesting 2518.92% upside. Our AI forecast model points to short-term weakness (-5.91% over two weeks), a medium-term rise (9.78% over three months), and a longer-term gain (20.23% over one year), with expected trading ranges indicating moderate volatility.